TARSUS PHARMACEUTICALS, INC. Earnings Per Share (Basic)
TARSUS PHARMACEUTICALS, INC. (TARS) reported Earnings Per Share (Basic) of -$0.43 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.43.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.16.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.30.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for the quarter ending 2025-06-30 was -$0.48.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2025 was -$1.59.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2024 was -$3.07.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2023 was -$4.62.
- TARSUS PHARMACEUTICALS, INC. earnings per share, basic for fiscal 2022 was -$2.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.43 10-Q · filed 2026-08-06 | -$0.59 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$0.16 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | -$1.59 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | -$0.30 10-Q · filed 2025-11-04 | -$1.40 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$0.48 10-Q · filed 2026-08-06 | -$1.11 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$0.64 10-Q · filed 2026-05-06 | ||||
| 2024-12-31 | -$3.07 10-K · filed 2026-02-23 | ||||
| 2024-09-30 | -$0.61 10-Q · filed 2025-11-04 | -$2.48 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$0.88 10-Q · filed 2025-08-06 | -$1.89 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$1.01 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$4.62 10-K · filed 2026-02-23 | ||||
| 2023-09-30 | -$1.28 10-Q · filed 2024-11-13 | -$3.35 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | -$1.17 10-Q · filed 2024-08-08 | -$2.05 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$0.88 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | -$2.52 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | -$0.84 10-Q · filed 2023-11-09 | -$1.11 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$2.03 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$0.24 10-Q · filed 2023-08-10 | -$1.15 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$0.98 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | -$0.67 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$0.76 10-Q · filed 2022-11-09 | -$0.46 derived: net income ÷ weighted average shares · filed 2022-11-09 | $0.05 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.31 10-Q · filed 2022-08-11 | $0.81 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$0.51 10-Q · filed 2022-05-11 | $0.51 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | -$4.32 10-K · filed 2022-03-14 | ||||
| 2020-09-30 | -$3.71 10-Q · filed 2021-11-10 | -$4.98 derived: net income ÷ weighted average shares · filed 2021-11-10 | -$5.73 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$1.23 10-Q · filed 2021-08-05 | -$1.96 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$0.74 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |